Novel strategy successfully suppresses HIV infection in mice
A new method, called synapse for T-cell activation (synTac), can attack HIV-infected T cells and may be a new cure for HIV and other diseases.
List view / Grid view
A new method, called synapse for T-cell activation (synTac), can attack HIV-infected T cells and may be a new cure for HIV and other diseases.
Washington University will receive $7.5 million from the NIH to study senescent cells for treatments against age-related diseases.
The statistical method known as maximum entropy could improve cryogenic electron microscopy (cryo-EM) for more effective drug treatments.
A new antiviral has shown promise against the dengue virus in mice and has the potential to be used as a preventative measure.
Mission Therapeutics was granted $500,000 from the The Michael J Fox Foundation for Parkinson’s Research for DUB inhibitor testing.
Scientists have identified the OAS1 gene as a risk factor for both Alzheimer's disease and COVID-19, suggesting potential drug targets.
Researchers have visualised SARS-CoV-2 protein dynamics using in silico methods. In this article, Navodya Roemer explains how a team from the University of Warwick developed a computational strategy that could assist scientists in the production of new treatments and drugs for COVID-19.
Landmark pre-clinical studies to investigate whether psychedelic derivatives can reduce alcohol consumption have been initiated.
Psilera will participate in two studies with the National Institute on Drug Abuse to combat addiction using a novel DMT formulation.
View Drug Target Review's new infographic on the use of AI and informatics within early therapeutic development here.
Research from Yale University has shown that psilocybin, given to mice, triggered an increase in connections between neurons.
One approach towards efficient drug targeting efforts for COVID-19 is to repurpose medicines developed for other diseases. Here, Professor Christopher Basler outlines a recent study, published in Cell Reports, where scientists from the Institute for Biomedical Sciences at Georgia State University, US, in collaboration with industry partners, developed assays to…
The European Medicines Agency is promoting three principles – replace, reduce and refine – to reduce animal testing in medicine development.
Organ-on-a-chip models can provide an alternative to cell cultures, animal models and traditional assays. In this article, Dr Désirée Goubert, Thomas Olivier, Luuk de Haan and Dr Lenie van den Broek explore the advantages of organ-on-a-chip technologies and how they can enable the in vitro study of three-dimensional (3D) cell migration in…
Dr Chetan Karyekar, Compound Development Team Leader at The Janssen Pharmaceutical Companies of Johnson & Johnson (J&J), explains how targeting underlying immune pathways can open the door to effectively treating more inflammatory bowel disease (IBD) patients by reducing or eliminating the chronic use of corticosteroids.